期刊一览

      Tozer ( p. 2029) 等人评估了新生血管性年龄相关性黄斑变性 (AMD) 患眼行补救治疗的有效性,这些患眼行单药治疗(玻璃体腔注射贝伐单抗或雷珠单抗)失败。他们发现,联合光动力治疗(PDT)及抗血管内皮生长因子(VEGF)药物治疗能有效提高患者视力,改善中心视网膜厚度,增加无液随访比例及延长治疗间隔时间。该回顾性、非对照性介入治疗病例中,26名患者26眼于7天内同时完成PDT和抗-VEGF治疗。联合治疗后第1及第3个月,视力有明显改善(有统计学意义);1、3、6个月黄斑中心视网膜厚度明显降低;无视网膜下液的随访数从0.5%提高至45%。总体而言,治疗间隔从联合治疗前平均1.6个月治疗一次延长至联合治疗后每2.7个月个月治疗一次。
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Linked Article

      • This Issue At A Glance
        OphthalmologyVol. 120Issue 10
        • In Brief
          Tozer et al (p. 2029) evaluated the effectiveness of rescue therapy in eyes with neovascular age-related macular degeneration (AMD) that failed monotherapy with intravitreal injections of bevacizumab or ranibizumab. They found that the combination of photodynamic therapy (PDT) and injections of anti–vascular endothelial growth factor (VEGF) agents resulted in improvements in visual acuity, central retinal thickness, number of fluid-free visits, and the length of time between treatments. In this retrospective, noncomparative, interventional case series, 26 eyes of 26 patients were identified as having had both PDT and anti-VEGF injections within a 7-day period.
        • Full-Text
        • PDF